|
|||||
|
|
Investigational drugs targeting fibroblast growth factor receptor in the treatment of non-small cell lung cancer |
|
| Authors: | Erika Rijavec Carlo Genova Giulia Barletta Federica Biello Giovanni Rossi Marco Tagliamento |
| Institution: | 1. UOS Tumori Polmonari, IRCCS AOU San Martino IST- Istituto Nazionale per la Ricerca sul Cancro, Genova, Italy;2. Dipartimento di Medicina Interna e Specialità Mediche (DIMI), Università di Genova, Genova, Italy |
| Abstract: | Introduction: Fibroblast growth factor receptor (FGFR) due to its central role in regulating cell survival, is a promising target for cancer therapeutics. Dysregulation of the FGFR pathway has been observed in several malignancies, including non-small cell lung cancer (NSCLC) particularly in patients with squamous histology. Areas covered: The aim of this article is to review the most relevant findings of clinical trials investigating drugs targeting FGFR pathway: such as FGFR tyrosine kinase inhibitors (TKIs), FGFR monoclonal antibodies and FGF ligand traps in NSCLC patients. Expert opinion: At present, clinical activity of drugs targeting FGFR in NSCLC is disappointing. Further studies are needed in order to better identify patients who might benefit from these drugs and to clarify the mechanisms of resistance to these compounds. |
| Keywords: | FGFR NSCLC FGFR TKI FGF |